Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of adverse events were mild and mainly occurred during the loading doses. Adverse events consisted of chills, itching and fatigue in over a third of patients. - There was a trend for increasing incidence of some mild adverse events with escalating OGX-427 doses. For example, 33% of patients at the 200-mg dose compared to 67% of patients at the 1000-mg dose had mild adverse events during the loading doses. - The half-life of OGX-427 in the blood remained constant, although there appeared to be an increase in maximum blood levels and a corresponding decease in blood clearance of OGX-427 as doses were escalated.

The combination of 800 mg OGX-427 with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

Circulating Tumor Cell and Tumor Marker Results

Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during treatment. Both total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in both total and Hsp27-positive CTCs were observed in over half of the patients in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or less cells occurred in 27% of patients who had greater than 5 CTCs at baseline.

Reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian cancer.

"CTCs are emerging as an exciting surrogate of anti-cancer activity. The frequent decreases in total
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... senior lecturer in mechanical engineering at the University of ... Year by the North Texas section of the American ... than 130,000 members in 158 countries who develop engineering ... the engineering community, benefiting the world. , ASME recognized ... Professional Engineers honors banquet. Baughn retired as an engineering ...
(Date:7/22/2014)... 2014 Rice Lake Weighing ... 2014 NCSL International Workshop and Symposium July 28-31 ... CONDEC pressure instrumentation, OIML M1 weights, precision lab ... customized sets, Essential Weights™. , NCSL International was ... in solving the common problems faced by measurement ...
(Date:7/22/2014)... og SHENZHEN , Kina, 22. ... LTD, (BGI Tech), et datterselskab af BGI, verdens ... ny human whole exome-sekvenseringstjeneste baseret på Complete Genomics ... anset i branchen for at levere patenterede sekvenseringsteknologier ... alle typer varianter, blev købt af BGI i ...
(Date:7/22/2014)... Switzerland (PRWEB) July 22, 2014 ... are becoming an increasingly common sight. The rapid ... they are now well- established as a core ... low maintenance has made them the gas analyzer ... locations and conditions encountered in some processes have ...
Breaking Biology Technology:UT Dallas professor receives Engineer of the Year award 2Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2
... 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical ... today announced its third quarter financial results for 2011. ... Nile reported research and development collaboration income relating to ... to none in the third quarter of 2010. The ...
... 13, 2011 Pharmasset, Inc. (Nasdaq: VRUS ) ... 8th Annual Healthcare Conference to be held November 15 to ... Pharmasset,s President and Chief Executive Officer, will provide an overview ... (ET). To access a simultaneous webcast of Mr. ...
... 2011 Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies -- today reported financial results for the three ... Recent and Upcoming Highlights ...
Cached Biology Technology:Nile Therapeutics Reports 2011 Third Quarter Financial Results 2Nile Therapeutics Reports 2011 Third Quarter Financial Results 3Nile Therapeutics Reports 2011 Third Quarter Financial Results 4Nile Therapeutics Reports 2011 Third Quarter Financial Results 5Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 3Spherix Announces Third Quarter Financial Results 2Spherix Announces Third Quarter Financial Results 3Spherix Announces Third Quarter Financial Results 4Spherix Announces Third Quarter Financial Results 5Spherix Announces Third Quarter Financial Results 6Spherix Announces Third Quarter Financial Results 7
(Date:7/22/2014)... 2014) New research from the Monell Center reveals ... can increase airway inflammation in asthmatics for at least ... that expectations can play in health-related outcomes. , "Asthmatics ... expect that an odor is harmful, our bodies react ... lead author Cristina Jan, PhD, a Monell physiologist. "Both ...
(Date:7/22/2014)... be good for the average steak, but it seems ... to survive Alaska,s winter cold. , "Alaska wood frogs ... steak does in your freezer and the frog comes ... than the steak," said Don Larson, University of Alaska ... paper demonstrating that freeze tolerance in Alaska wood frogs ...
(Date:7/22/2014)... to dust mites (and chances are you are), help ... University of Iowa have developed a vaccine that can ... response. In animal tests, the nano-sized vaccine package lowered ... the allergens, according to the paper, published in the ... Journal . One big reason why it works, the ...
Breaking Biology News(10 mins):In asthma, it's not just what you smell, but what you think you smell 2In asthma, it's not just what you smell, but what you think you smell 3Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Researchers create vaccine for dust-mite allergies 2
... (Boston) A new study from Boston University School ... pluripotent stem (iPS) cells in an experimental model were ... The study, published online in Cell Stem Cell ... develop cell types that could offer treatment for a ...
... new study that provides surprising details on changes in Earth,s ... last interglacial--the period between "ice ages"--was warmer than previously thought ... greenhouse gases increase in the atmosphere and global temperatures rise. ... the massive West Antarctic ice sheet may have contributed more ...
... led by Associate Professor Kenji Osafune and his colleague ... and Application (CiRA), Kyoto University in Japan, has succeeded ... induced pluripotent stem (iPS) cells to differentiate into intermediate ... lineages. This represents a major step toward realizing renal ...
Cached Biology News:BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection 2Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 2Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 3Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 4Monitoring and robust induction of nephrogenic intermediate mesoderm from human iPSCs 2
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... an evolutionarily conserved form of cell suicide, ... The central component of this process is ... These enzymes participate in a series ... to pro-apoptotic signals and result in the ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
...
Biology Products: